NNMT inhibition · Small molecule
Evidence gap: Route-specific human PK and absolute bioavailability are not established in the imported material.
Open in the interactive library →Compare with other compounds →
The guide describes predominantly preclinical adipose and metabolic research.
Context: No primary study identifier supplied for this entry.
Limitations: Human injectable PK, safety and dose-response are not established.
5-amino-1MQ lowered NNMT reaction product 1-MNA in cultured adipocytes; the study also reported altered NAD+ and SAM signaling and reduced lipogenesis with NNMT inhibitors.
Context: Neelakantan et al. 2018; cultured cells and diet-induced obese mice, not established human outcomes.
Limitations: Do not infer human efficacy or a validated therapeutic dose. Exact in-vivo salt, route, mass normalization and study endpoints await full-text audit.
Open this exact record in the library →Suggest a correctionTreatment with a potent NNMT inhibitor reduced weight, white adipose mass, adipocyte size and total cholesterol in diet-induced obese mice; food intake was not altered in the reported model.
Context: Neelakantan et al. 2018; preclinical high-fat-diet mouse model.
Limitations: No established human weight-loss efficacy; the precise treatment schedule should be recorded only after full methods and molecular identity are reconciled.
Open this exact record in the library →Suggest a correctionIn a rat pharmacokinetic study, 5-amino-1MQ mean oral bioavailability was 38.4%; terminal half-lives were 3.80 ± 1.10 hours IV and 6.90 ± 1.20 hours oral.
Context: Awosemo et al. 2021; rat IV and oral pharmacokinetics, PMID 34304009.
Limitations: These rat measurements do not establish human absorption, an oral-to-SC conversion, timing, or any human dose.
Open this exact record in the library →Suggest a correctionPublic community and vendor descriptions report oral amounts such as 25 mg twice daily, 50 mg once or twice daily, and 50 mg three times daily; some mention 4–12 week cycles.
Context: Unverified community claim summary from 2026-11-01 sweep; individual source URLs/posts were not preserved for this claim.
Limitations: UNVERIFIED: not a validated or recommended human protocol; no firsthand post/transcript attribution, purity, formulation or safety confirmation. Do not enable as calculator default.
Community discussions describe 150–500 mcg, 1–2 mg, 2.5–5 mg and occasional 5–15 mg SC amounts with varying frequencies.
Context: Unverified community claim summary from 2026-11-01 sweep; no attributable post URLs preserved.
Limitations: UNVERIFIED: salt, concentration and administered units are uncertain; do not use as injectable guidance or calculator preset.
Some users claim energy, endurance or fat-loss changes; others report no effect or gastrointestinal symptoms, dizziness, insomnia, palpitations, fatigue or local reactions. Online stacks mention retatrutide, MOTS-c and NAD+.
Context: Anecdotal and confounded online reports; platform-wide scrape and individual-post verification not completed.
Limitations: UNVERIFIED: no causality, prevalence, interaction safety or combination efficacy established; no human safety profile or validated protocol.
These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.